Skip Navigation

Neuro-Oncology 2009 11(2):192-200; doi:10.1215/15228517-2008-086
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrowScopus Links
Google Scholar
Right arrow Articles by Pezzolo, A.
Right arrow Articles by Gambini, C.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Pezzolo, A.
Right arrow Articles by Gambini, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright 2009 by the Society for Neuro-Oncology

Presence of 1q gain and absence of 7p gain are new predictors of local or metastatic relapse in localized resectable neuroblastoma

Annalisa Pezzolo, Elena Rossi, Stefania Gimelli, Federica Parodi, Francesca Negri, Massimo Conte, Angela Pistorio, Angela Sementa, Vito Pistoia, Orsetta Zuffardi and Claudio Gambini

Departments of Oncology (A.P., F.P., V.P.) and Pathology (F.N., A.S., C.G.), Hematology-Oncology Unit (M.C.), and Epidemiology and Biostatistics Unit (A.P.), IRCCS G. Gaslini Hospital, Genoa; Medical Genetics Department, University of Pavia, Pavia (E.R., S.G., O.Z.); Italy

Address correspondence to Annalisa Pezzolo, IRCCS G. Gaslini Hospital, Largo G. Gaslini, 5, 16147 Genova-Quarto, Italy (annalisapezzolo{at}ospedale-gaslini.ge.it).


  Abstract

We have addressed the search of novel genetic prognostic markers in a selected cohort of patients with stroma-poor localized resectable neuroblastoma (NB) who underwent relapse or progression (group 1) or complete remission (group 2) over a minimum follow-up of 32 months from diagnosis. Twenty-three Italian patients with localized resectable NB (stages 1 and 2) diagnosed from 1994 through 2005 were studied. All patients received surgical treatment. Chemotherapy was administered only to the three stage 2 patients who had MYCN-amplified tumors. High-resolution array-comparative genomic hybridization (CGH) DNA copy-number analysis technology was used to identify novel prognostic markers. Chromosome 1p36.22p36.32 loss and 1q22qter gain, detected almost exclusively in group 1 patients, were significantly associated with poor event-free survival (EFS) (p = 0.0024 and p = 0.024, respectively). In contrast, patients with 7p11.2p22 gain, who belonged predominantly to group 2, had a significantly better EFS (p = 0.015). The frequency of 17q gain or 3p and 11q losses did not differ significantly in group 1 versus group 2 NBs. The sensitive technique allowed us to define the smallest region of 1p deletion. In conclusion, 1q22qter gain and 7p11.2p22 gain might represent new prognostic markers in localized resectable NB, but the small study size and the retrospective nature of the findings warrant further validation of the results in larger studies.

Keywords: 1q gain, 7p gain, array-CGH, localized resectable neuroblastoma, prognostic markers

Received February 3, 2008; Accepted April 29, 2008


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.